Welcome to our dedicated page for Teva Pharmaceutical Industries American Depositary Shares news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries American Depositary Shares stock.
Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is a leading Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. As the world's largest generic drug manufacturer, Teva plays a pivotal role in the global healthcare industry. The company derives approximately 50% of its sales from North America, contributing significantly to the total number of generic prescriptions in the United States.
Teva's extensive portfolio includes not only generic drugs but also active pharmaceutical ingredients (APIs) and proprietary pharmaceuticals. The company's operations are categorized into three main therapeutic areas:
- Central Nervous System (CNS): Featuring notable products such as Copaxone, Ajovy, and Austedo, Teva addresses critical CNS disorders with innovative treatments.
- Respiratory: Products like Qvar and ProAir contribute to Teva's robust respiratory medicine lineup, catering to patients with various respiratory conditions.
- Oncology: Teva's oncology portfolio includes groundbreaking medicines such as Truxima, Herzuma, and Bendeka/Treanda, providing essential treatments for cancer patients.
In addition to its pharmaceutical products, Teva is a major player in active pharmaceutical ingredients, offering contract manufacturing services and owning Anda, a U.S.-based distributor of generic and specialty drugs.
Teva's global presence extends beyond North America, with significant operations in Europe, Japan, Russia, and its home country, Israel. The company's strategic partnerships and innovations keep it at the forefront of the pharmaceutical industry. Recent developments include advancements in biosimilars and innovative treatments.
Financially, Teva continues to maintain a strong position, focusing on growth and resilience amidst market challenges. The company is committed to improving patient health worldwide by providing high-quality, affordable medicines.
Rhea-AI Summary
Teva Pharmaceuticals' AJOVY shows efficacy in Phase 3 study, reducing migraine days significantly. The drug met primary and secondary endpoints, demonstrating superior efficacy over placebo. AJOVY also displayed a favorable safety profile. The study targeted adult Chinese patients, with positive results indicating potential global impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical Industries (TEVA) will release its first quarter 2024 financial results on May 8, 2024, followed by a conference call and webcast. Participants can register in advance for the call and access the webcast on Teva's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
-
Rhea-AI Summary
Teva Pharmaceuticals presents data on UZEDY, an extended-release injectable suspension of risperidone, for the treatment of schizophrenia in adults. The data includes insights on dosing conversions and strategies for switching from a long-acting injectable formulation. The presentation at the SIRS 2024 Congress highlights the efficacy and safety profile of UZEDY, emphasizing its potential to reduce relapse rates and hospitalizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
Teva Pharmaceuticals and mAbxience collaborate on a biosimilar candidate for oncology treatment, aiming to provide cost-effective alternatives globally. The partnership supports Teva's growth strategy and mAbxience's expansion plans, emphasizing a commitment to improving healthcare access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical Industries and Launch Therapeutics collaborate to advance Teva's Dual-Action Asthma Rescue Inhaler program TEV-‘248, with a strategic funding agreement of up to $150 million. The program aims to be the first ICS-SABA for both adult and pediatric asthma indications, combining fluticasone propionate and albuterol sulfate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
-
News
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. forms a partnership with Jiangsu Nhwa Pharmaceutical Co., Ltd. to market and distribute AUSTEDO for neurodegenerative and movement disorders in China. AUSTEDO, a deuterated drug, targets chorea associated with Huntington’s disease and tardive dyskinesia, offering innovative treatment options. The partnership aims to enhance patient access to AUSTEDO in China's neuro-psychiatric health sector, leveraging Nhwa's expertise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.1%
Tags
Rhea-AI Summary
Teva Pharmaceuticals announces positive safety and tolerability data for anti-TL1A (TEV-'574) in inflammatory bowel disease, demonstrating rapid and sustained suppression of free TL1A. The asset shows a well-tolerated safety profile and supports ongoing Phase 2b clinical investigation. Teva also disclosed a collaboration deal with Sanofi for co-development and co-commercialization of anti-TL1A (TEV-'574) for UC and CD, with significant financial implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
-
Rhea-AI Summary
Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., has been named to Forbes list of Canada’s Best Employers 2024, ranking No. 1 of Drugs & Biotechnology employers and No. 28 of 300 overall employers. Forbes and Statista Inc. conducted independent surveys of over 40,000 Canada-based employees from companies employing at least 500 people in all industry sectors, with over 900,000 employer evaluations considered.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary
Teva Pharmaceutical Industries Ltd. reported a 7% increase in local currency terms for 2023 revenues of $15.8 billion compared to 2022. AUSTEDO® exceeded $1.2 billion in annual revenues, up 28% from 2022. The company expects strong growth to continue in 2024 with expected revenues of ~$1.5 billion. AJOVY® had global annual revenues of $435 million, up 16% from 2022. The generics business stabilized, with back-to-revenue growth in Q4 2023. The ongoing net debt reduction reduced to $16.6 billion as of December 31, 2023. The company's pivot to growth strategy is in action, with Teva api intended divestiture to focus on core business strengths and capital allocation towards growth engines and innovation. The company also entered into exclusive collaborations with Sanofi and Royalty Pharma, and a license agreement with Biolojic Design for potential treatments of Atopic Dermatitis and Asthma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
Rhea-AI Summary
Teva announced its intention to divest its active-pharmaceutical ingredient (API) business, or 'TAPI', to focus on core business strengths, capital allocation towards growth and innovation, and better serve patients. The divestiture is expected to enhance TAPI's position as a global leader in the growing API market and create additional value for Teva’s shareholders and stakeholders. The intended divestiture is expected to be completed in the first half of 2025, subject to reaching a satisfactory agreement on transaction terms with a prospective purchaser and the approval of an agreed transaction by Teva’s Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
FAQ
What is the current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?
The current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is $22.09 as of December 20, 2024.
What is the market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?
The market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is approximately 24.7B.
What does Teva Pharmaceutical Industries Limited specialize in?
Teva specializes in generic drugs, active pharmaceutical ingredients, and proprietary pharmaceuticals.
Where is Teva headquartered?
Teva is headquartered in Tel Aviv, Israel.
What are some of Teva's key products?
Key products include Copaxone, Ajovy, Austedo, Qvar, ProAir, Truxima, Herzuma, and Bendeka/Treanda.
In which regions does Teva operate?
Teva operates in North America, Europe, Japan, Russia, and Israel.
How much of Teva's sales come from North America?
Approximately 50% of Teva's sales come from North America.
What therapeutic areas does Teva focus on?
Teva focuses on central nervous system, respiratory, and oncology therapeutic areas.
What is Anda?
Anda is a U.S.-based distributor of generic and specialty drugs owned by Teva.
Does Teva offer contract manufacturing services?
Yes, Teva offers contract manufacturing services.
What role does Teva play in the U.S. generic prescription market?
Teva accounts for a high-single-digit percentage of the total number of generic prescriptions in the U.S.
What recent advancements has Teva made?
Teva has made advancements in biosimilars and innovative treatments across its therapeutic areas.
Teva Pharmaceutical Industries Limited American Depositary Shares
NYSE:TEVA
TEVA Rankings
TEVA Stock Data
24.72B
1.13B
0%
57.83%
1.87%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States of America
TEL AVIV